NCT07073183 is a Phase 1 clinical trial of CV09070101 mRNA vaccine (CVHNLC) 50 µg in Squamous NSCLC, sponsored by CureVac.

Who is sponsoring NCT07073183?

NCT07073183 is sponsored by CureVac.

What drugs are being tested in NCT07073183?

Interventions in NCT07073183: CV09070101 mRNA vaccine (CVHNLC) 50 µg, CV09070101 mRNA vaccine (CVHNLC) 100 µg, CV09070101 mRNA vaccine (CVHNLC) 200 µg, CV09070101 mRNA vaccine (CVHNLC) 400 µg, CV09070101 mRNA vaccine (CVHNLC) 400 µg.

What condition does NCT07073183 study?

NCT07073183 studies Squamous NSCLC.

Is NCT07073183 still recruiting?

NCT07073183 is currently not yet recruiting. Last updated 18 July 2025.

Last reviewed 2025-07-18 · How we verify

NCT07073183

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)

Not yet recruiting Phase 1 Last updated 18 July 2025

What this trial tests

Phase 1 trial testing CV09070101 mRNA vaccine (CVHNLC) 50 µg in Squamous NSCLC in 36 participants. Not yet recruiting.

Timeline

30 July 2025

Primary endpoint
31 December 2029

31 December 2029

Quick facts

Lead sponsor	CureVac
Phase	Phase 1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	30 July 2025
Primary completion	31 December 2029
Estimated completion	31 December 2029
Sites	13 locations across France, United States, Spain

Drugs / interventions tested

CV09070101 mRNA vaccine (CVHNLC) 50 µg — full drug profile →
CV09070101 mRNA vaccine (CVHNLC) 100 µg — full drug profile →
CV09070101 mRNA vaccine (CVHNLC) 200 µg — full drug profile →
CV09070101 mRNA vaccine (CVHNLC) 400 µg — full drug profile →
CV09070101 mRNA vaccine (CVHNLC) 400 µg — full drug profile →

Conditions studied

Squamous NSCLC — all drugs for Squamous NSCLC →

Sponsor

CureVac — full company profile →

Who can join

18 and older, any sex, with Squamous NSCLC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, first-in-human, dose escalation study of CV09070101 mRNA (CVHNLC) in patients with metastatic Squamous Non-Small-Cell Lung Cancer (sqNSCLC). The study will evaluate the safety and tolerability of CVHNLC plus pembrolizumab in an Dose Escalation Part and, once the safety of this combination is established, CVHNLC plus prembrolizumab and chemotherapy (carboplatin and paclitaxel) will be evaluated in an Dose Expansion Part with the recommended dose selected from the Dose Escalation Part.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Advancing Lung Cancer Treatment: mRNA Therapeutics and Delivery Strategies.
Yaremenko AV, Pechnikova NA, Liu C. · · 2025 · cited 1× · PMID 41124104 · DOI 10.1021/acs.nanolett.5c03826
Emerging Immunotherapy and Antibody-Derived Therapeutics for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Review.
Hou AY, Elantably D, Manochakian R, Velcheti V, et al · · 2026 · PMID 42073614 · DOI 10.3390/cancers18081291
Nanovaccines for lung cancer: Platforms, mechanistic insights, and translational challenges
Hosseinalizadeh H, Ge F, Davari M, Liu X, et al · · 2026
Directions of Immunotherapy for Non-Small-Cell Lung Cancer Treatment: Past, Present and Possible Future.
Leone GM, Scuderi G, Fagone P, Mangano K. · · 2025 · PMID 41303538 · DOI 10.3390/ijms262211055

Verify or expand the search:

Other CureVac trials

Trials by the same sponsor.

NCT05938387 — Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma · Phase 1 · completed
NCT05252338 — A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy Adults · Phase 1 · completed
NCT04860258 — COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults · Phase 3 · terminated
NCT04674189 — A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19 · Phase 3 · completed
NCT04652102 — A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and S · Phase 2, PHASE3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07073183 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CureVac
Last refreshed: 18 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07073183.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing